by Amy Berger | Jan 27, 2021 | Blog, News
IITRI now offers an improved efficacy assay for looking at effects of drugs on SARS-CoV-2. Although this assay no longer includes a cytotoxicity readout, we offer a neutral red assay in BSl-2 instead if needed. This current assay uses immunostaining and provides more...
by Amy Berger | Oct 26, 2020 | Blog, Events, News
Even though we were saddened to hear that the 41st Annual Meeting of the American College of Toxicology (Nov 12-19) will not take place in the wonderful city of Austin this year, we support this decision and are very much looking forward to participating in the...
by Amy Berger | Aug 6, 2020 | Blog, News
Ferret infection model: Since early in the pandemic, IITRI has been working on developing new animal models to test out therapeutics and treatments for COVID-19 (in addition to in vitro offerings of efficacy assays, neutralization assays, and surface decontaminant...
by Amy Berger | Aug 5, 2020 | Blog, News
IITRI is proud to share the promising news of one of our partners, Moleculin! Our team here at IITRI was contracted to perform additional in vitro testing of their drug candidate (WP1122) for antiviral effects against SARS-CoV-2. We used growth medium that more...
by Amy Berger | Jul 13, 2020 | Blog, News
IITRI now offers an improved bleomycin (BLM) induced pulmonary fibrosis mouse model that can recapitulate many of the complex profibrotic responses that are also observed in the lungs of those suffering from idiopathic pulmonary fibrosis (IPF) and perhaps COVID-19...
by Amy Berger | Mar 19, 2020 | Blog, News
IITRI is now in custody of the a SARS-CoV-2 strain responsible for COVID-19. Our team is working on characterizing the strain for in vitro studies and in vivo modeling to test current vaccines and antivirals in addition to developing new treatments for this...
Recent Comments